VRAX

$VRAX chatter on StockTwits

• 
  Mamba Mentality@KobeTheGoatBullish59m

  $INFQ Always do the opposite of what @nakayama and @Tokoyama do - those idiots have been losing for years and never win!!!! Bunch of loser scammers, AND THESE ARE FACTS!!! Don't believe me? go look at what I did to these 2 with $VRAX - they lost it all like the 2 dumbasses they are!!!! Ran their trash from $9 to a reverse split, while they were claiming $100's inbound...Their "army" folded and then collapsed in ruins!

  View on StockTwits ↗
• 
  CoffeeRocks@CoffeeRocksBullish3h

  $AEMD $BTAI $CODX $EBS $VRAX

  View on StockTwits ↗
• 
  CoffeeRocks@CoffeeRocksBullish6h

  $CODX $AEMD $BTAI $VRAX $GOVX https://share.google/OJDYubJ7LmVHB0c0r

  View on StockTwits ↗
• 
  CoffeeRocks@CoffeeRocksBullish2d

  $EBS $VRAX $ISPC $CODX $AEMD Get ready for YeaR of the ViRuS 🦠 https://share.google/yHFYfMR3ycFbJw0Fh

  View on StockTwits ↗
• 
  CoffeeRocks@CoffeeRocksBullish3d

  $AEMD $CODX $EBS $GOVX $VRAX Ebola in the 📰 again ☝️ https://share.google/uSt2UocoSjyUk3zQ3

  View on StockTwits ↗
• 
  MEB@TraderBuckNKY4d

  $VRAX Balance Sheet Relative to Planned Near-Term Milestones: • Approximately $6.4 million in cash and no debt as of March 2026, with management believing the Company has runway to planned near-term milestones. • Expected average monthly burn of $220,000 supports the Company’s planned capital-efficient operating profile. • The Company completed a $5.0 million PIPE financing in December 2025, strengthening its cash position ahead of planned clinical, regulatory and commercial milestones

  View on StockTwits ↗
• 
  MEB@TraderBuckNKY4d

  $VRAX • Clinical Validation & Strategic Academic Partnerships • Virax is generating clinical and analytical data intended to support its planned U.S. LDT launch and future regulatory • The Company’s clinical work includes studies and collaborations involving Emory University and UK NHS-linked clinical study sites. • These studies are designed to help establish the evidence base for ViraxImmune™ and support future physician adoption, reimbursement discussions and regulatory • Planned Regulatory and Commercial Milestones Through 2028 • Near-term: clinical and analytical data readouts and S. LDT launch preparation (2026-2027) • Mid-term: planned S. LDT commercial launch and initial commercial ramp (targeted 2027) • Long-term: planned FDA De Novo regulatory pathway, subject to regulatory review and clearance (targeted 2028) • The Company may evaluate potential expedited regulatory pathways;

  View on StockTwits ↗
• 
  MEB@TraderBuckNKY4d

  $VRAX Scalable Central Laboratory Business Model. Virax plans to run testing through a central laboratory model, allowing physicians to order the test and send samples for analysis rather than requiring hospitals,clinics to install new equip. This approach is designed to support U.S. availability with lower infrastructure requirements and a more scalable commercial model. Revenue Opportunity Based on Adoption Assumptions. Based on management’s assumptions, modest S. LDT adoption could translate into meaningful revenue if Vmax is successfully commercialised. The Company’s U.S. LDT service revenue framework assumes 1%-2% penetration of annual PAIS incidence, representing approximately $13.4 million-$26.8 million in potential annual. Longer-term penetration of 1%-2% of the existing PAIS patient population would represent approximately 210,000-420,000 tests and a potential opportunity of approximately $112.4 million-$224.7 million, subject to validation, reimbursement, market adoption.

  View on StockTwits ↗
• 
  MEB@TraderBuckNKY4d

  $VRAX • Virax’s management believes the LDT pathway may provide a more capital-efficient route to initial S. commercialisation than a traditional FDA IVD pathway. • Potential To Reduce Diagnostic Burden and Support Reimbursement • PAIS patients often undergo multiple physician visits, specialist consultations, blood panels, imaging and functional tests before receiving a diagnosis, creating a costly and inefficient exclusion-based • Management estimates, the current cost of diagnostic exclusion can range from approximately $5,900-$27,450 per patient on an uninsured-cost • If successfully validated and commercialised, ViraxImmune™ could support a more targeted objective testing pathway, with management estimating a reduction in pathway cost to approximately $525-$1,200 per patient, including associated consultation, testing and blood draw costs. • For its planned initial S. LDT launch, Virax’s current model assumes reimbursement of approximately $812 per test using a billing code.

  View on StockTwits ↗
• 
  MEB@TraderBuckNKY4d

  $VRAX Potential First-in-Category Assay in a Large, Underserved Diagnostic Category (PAIS) Targeting post-acute infection syndromes (PAIS), including Long COVID, ME/CFS, and post-treatment Lyme disease — conditions affecting millions of patients and currently lacking widely adopted objective diagnostic tests. Expert estimates suggest the S. economic burden associated with these conditions exceeds $25 billion annually. PAIS conditions are estimated to affect approximately 21 million people in the U.S., with approximately 5 million new cases annually. ViraxImmune™ to address this unmet need through objective immune dysfunction profiling. Capital-Efficient Planned U.S. Market Entry via LDT Pathway. Pursuing a planned U.S. laboratory-developed test (LDT) pathway as an initial market-entry strategy while generating data to support future regulatory Targeting U.S. LDT launch in 2027, subject to validation, laboratory implementation, reimbursement, regulatory considerations and execution.

  View on StockTwits ↗
• 
  CoffeeRocks@CoffeeRocksBullish4d

  $CODX $GOVX $VRAX $EBS $AEMD

  View on StockTwits ↗
• 
  jo@shuffle135d

  $GOVX Reuters now reporting on ebola $CODX $VRAX https://www.reuters.com/podcasts/chasing-ebola-2026-08-08/?utm_source=Facebook&utm_medium=Social&utm_medium=Social&utm_source=twitter

  View on StockTwits ↗
• 
  Gary Best@garygbBullish5d

  $VRAX Buying and holding.

  View on StockTwits ↗
• 
  CoffeeRocks@CoffeeRocksBullish6d

  $CODX $VRAX $AEMD $EBS $ISPC https://www.science.org/content/article/smallpox-may-be-gone-u-s-should-better-prepare-its-return-report-says

  View on StockTwits ↗
• 
  Jose Berrios@dario2580Bullish6d

  $VRAX any news and this should go

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.